Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2018

The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. Introduction of targeted therapy has revolutionized treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Further key findings from the report suggest:

EU5 will remain the second largest market with more than 30% share by 2023. The growth of the segment can be attributed to rising incidence of STS, uptake of targeted therapies, and increasing R&D activities

Eli Lilly’s Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period

Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials

The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials

Companies with late-stage pipeline products for sarcoma are likely to enter the market by 2019 and would capture more than 10.0% of the sarcoma market share in 2023

Drugs with novel targets in early-phase development include Novartis’s Afinitor (mTOR inhibitor), Tesaro’s Zejula (PARP inhibitor), Amgen’s Imlygic (gene therapy), and Pfizer’s Crizotinib (ALK and MET tyrosine kinases inhibitor)

Role of VEGF inhibitors and mTOR inhibitors is under evaluation in multiple early phase trials. However, no statistically significant data has been reported till date

This product will be delivered within 1-3 business days.

Chapter 1 Research Methodology

1.1. Information procurement
1.2. Information or Data Analysis
1.2.1. Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

3.1 Disease Primer
3.1.1 Soft Tissue Sarcoma (STS)
3.1.2 Bone Sarcoma
3.1.3 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S.,Japan,EU5)

Chapter 4 Global Sarcoma Drugs Market Overview

4.1 Sarcoma Drugs Market Overview
4.1.1 Tyrosine kinase inhibitors (c-KIT, PDGFR, and VEGF inhibitors)
4.1.2 Cell Cycle Inhibitors
4.1.3 mTOR inhibitors
4.2 Market, by Treatment Type
4.3 Market Size and Forecast (2017 - 2023)
4.4 Market Size and Forecast, by Seven Major Markets (2017 - 2023)
4.4.1 U.S. Sales by Treatment Type (2017 - 2023)
4.4.2 U.K. Sales by Treatment Type (2017 - 2023)
4.4.3 Germany Sales by Treatment Type (2017 - 2023)
4.4.4 France Sales by Treatment Type (2017 - 2023)
4.4.5 Italy Sales by Treatment Type (2017 - 2023)
4.4.6 Spain Sales by Treatment Type (2017 - 2023)
4.4.7 Japan Sales by Treatment Type (2017 - 2023)
4.5 Market Share Distribution, by Company (2017 - 2023)
4.6 Market Dynamics and Brand Strategies
4.7 Patent Expiry Analysis
4.8 Sarcoma Drugs Market: Drivers and Restraints
4.8.1 Market Drivers
4.8.2 Market Restraints
4.9 M&A, Deal Landscape (2013-2018 YTD)
4.9.1 Mergers & Acquisitions
4.9.2 Deals Landscape
4.10 Pricing and Reimbursement Scenario
4.11 Sarcoma Sector SWOT

Chapter 5 Sarcoma Drugs Market: Pipeline Intelligence

5.1 Pipeline Landscape
5.1.1 Leading Drugs in Development
5.2 Key R&D Trends
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.2.3 Immunotherapy
5.2.3.1 Immuno-oncology agents
5.2.3.2 Cancer Vaccines
5.2.3.3 Gene Therapy
5.3 Pipeline Landscape
5.3.1 Late Stage Pipeline Drugs
5.4 Clinical Profiles of Disruptive Drugs
5.5 Global Pipeline Forecast

Chapter 6 Company Profiles

6.1 Novartis
6.1.1 Company Overview
6.1.2 Product Portfolio
6.1.3 Product Forecast Sales through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis and Overview
6.1.6 SWOT
6.2 Pfizer
6.2.1 Company Overview
6.2.2 Product Portfolio
6.2.3 Product Forecast Sales through 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis and Overview
6.2.6 SWOT
6.3 Eli Lilly
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales through 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.4.2 Catalysts & Events Calendar
6.3.5 Pipeline Analysis and Overview
6.3.6 SWOT
6.4 Eisai
6.4.1 Company Overview
6.4.2 Product Portfolio
6.4.3 Product Forecast Sales through 2023
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 Pipeline Analysis and Overview
6.4.6 SWOT
6.5 Johnson & Johnson
6.5.1 Company Overview
6.5.2 Product Portfolio
6.5.3 Product Forecast Sales through 2023
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.5 Pipeline Analysis and Overview
6.5.6 SWOT
6.6 Bayer
6.6.1 Company Overview
6.6.2 Product Portfolio
6.6.3 Product Forecast Sales through 2023
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.5 Pipeline Analysis and Overview
6.6.6 SWOT

Chapter 7 Market Outlook

7.1. What the Future Holds
7.2. The Winners and Losers
7.2.1. Winners
7.2.2. Losers
7.3. Emerging Companies/New Technology Platforms
7.4. The Road Ahead

List of Tables

Table 1 Sarcoma - Classification
Table 2 Soft-Tissue Sarcoma - Staging and Five-Year Survival Rate
Table 3 Bone Sarcoma - Staging and Five-Year Survival Rate
Table 4 First-line Chemotherapy for Sarcoma (Generics)
Table 5 Marketed Drugs for Sarcoma
Table 6 Sales by Treatment Type, in $ Million, 2017 - 2023
Table 7 Sales Performance by Country, in $ Million, 2017 - 2023
Table 8 U.S., Sales by Treatment Type (2017 - 2023)
Table 9 U.K., Sales by Treatment Type (2017 - 2023)
Table 10 Germany, Sales by Treatment Type (2017 - 2023)
Table 11 France, Sales by Treatment Type (2017 - 2023)
Table 12 Italy, Sales by Treatment Type (2017 - 2023)
Table 13 Spain, Sales by Treatment Type (2017 - 2023)
Table 14 Japan, Sales by Treatment Type (2017 - 2023)
Table 15 Patent Expiry Analysis
Table 16 R&D Pipeline Overview - Leading Drugs
Table 17 Late Stage Pipeline Analysis
Table 18 BLU-285 (avapritinib)
Table 19 INNO-206 (Aldoxorubicin)
Table 20 TRC105 (carotuximab)
Table 21 Pipeline Forecast
Table 22 Novartis Product Forecast Sales (2017 - 2023)
Table 23 Pfizer Product Forecast Sales (2017 - 2023)
Table 24 Eli Lilly Product Forecast Sales (2017 - 2023)
Table 25 Eisai - Product Forecast Sales (2017 - 2023)
Table 26 Johnson & Johnson Product Forecast Sales (2017 - 2023)
Table 27 Bayer Product Forecast Sales (2017 - 2023)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Sarcoma Major Subtypes
FIG. 8 U.S. - Soft Tissue Sarcoma Incidence and Mortality Trends
FIG. 9 U.S. - Bone Sarcoma Incidence and Mortality Trends
FIG. 10 U.K.- STS Incidence Rates per 100,000 Population, by Sex
FIG. 11 U.K.-Bone Sarcoma Incidence Rates per 100,000 Population, by Sex
FIG. 12 Germany- Sarcoma Incidence and Mortality Trends
FIG. 13 Germany- Age-Standardized Incidence Rate per 100,000 people
FIG. 14 France - STS Age-Standardized Incidence Rate per 100,000 people
FIG. 15 Japan - Sarcoma Incidence Trends
FIG. 16 Treatment Type, Market Share Distribution, 2017 and 2023
FIG. 17 Regional Market Size, 2017 & 2023
FIG. 18 Market Shares Distribution, by Company (2017 & 2023)
FIG. 19 Sarcoma Sector SWOT
FIG. 20 Sarcoma R&D Pipeline - Drugs in Development
FIG. 21 Sarcoma R&D Pipeline, by Treatment Type
FIG. 22 Immunotherapy Types In Development for Sarcoma Treatment
FIG. 23 Novartis Sarcoma Sales Forecast
FIG. 24 Novartis SWOT Analysis
FIG. 25 Pfizer Sarcoma Sales Forecast
FIG. 26 Pfizer SWOT Analysis
FIG. 27 Eli Lilly Sarcoma Sales Forecast
FIG. 28 Eli Lilly SWOT Analysis
FIG. 29 Eisai Sarcoma Sales Forecast
FIG. 30 Eisai SWOT Analysis
FIG. 31 Johnson & Johnson Sarcoma Sales Forecast
FIG. 32 Johnson & Johnson SWOT Analysis
FIG. 33 Bayer Sarcoma Sales Forecast
FIG. 34 Bayer SWOT Analysis

Companies Mentioned

Novartis
Pfizer
Eli Lilly
Eisai
Johnson & Johnson
Bayer

Methodology

LOADING...

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2018 - 2023

Table of Contents

Companies Mentioned

Methodology

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Sarcoma Drugs - Global Strategic Business Report

Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Sarcoma Drugs Market By Disease Indication, By Treatment, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031

Global Bone Cancer Treatment Market by Type (Chondrosarcoma, Ewing's Sarcoma, Multiple Myeloma), Treatment (Chemotherapy, Radiation Therapy, Surgery), Distribution Channel - Cumulative Impact of High Inflation - Forecast 2023-2030